300750 Contemporary Amperex Technology (A)

DGAP-News: Vivera Pharmaceuticals Welcomes His Excellency Salah Al Shamsi to Its Advisory Board

DGAP-News: Vivera Pharmaceuticals, Inc. / Key word(s): Miscellaneous
Vivera Pharmaceuticals Welcomes His Excellency Salah Al Shamsi to Its Advisory Board

01.10.2019 / 15:10
The issuer is solely responsible for the content of this announcement.


Newport Beach, California--(Newsfile Corp. - October 1, 2019) - ., a pharmaceutical company focused on non-addictive pain management is pleased to announce the appointment of His Excellency Salah Salem Bin Omair Al Shamsi to the Company's Advisory Board. A prominent business leader with unparalleled high level expertise, a large part of his role at Vivera will be to further the Company's international business development efforts.

An illustrious career that spans over 35 years, H.E. Al Shamsi is known for his keen business acumen and ability to consistently exceed challenging goals. He started his career in 1981 at the Abu Dhabi National Oil Company (ADNOC). He then served as the Executive Director of the Hydrocarbon Processing Directorate from 1984 to 1990 and was appointed Executive Director of projects from 1990 to 1996. In his 15 plus years at ADNOC, he was responsible for large projects in excess of USD$1 billion and he brought about significant cost reductions while simultaneously improving systemic efficiency.

Regarded as an expert in the petrochemical sector, he was granted the "World Safety Organization Award" for his efforts in increasing safety levels in the Refinery and Gas Plant Operations. As the Chairman and Managing Director of Emirates Global Capital Corporation Ltd., H.E. Al Shamsi led the development of Saadiyat Island in 1999, one of the most ambitious projects in the UAE. He formerly served as both the President of Abu Dhabi's Chamber of Commerce and President of the Gulf Cooperation Counsel's Chamber of Commerce. Today, His Excellency is actively involved in private businesses across a variety of sectors.

"It is a true honor to have His Excellency join our advisory board," said Paul Edalat, Chairman and Founder of Vivera. "With his dedication to success and eminent international expertise, I have no doubt that Vivera will benefit greatly from his expertise."

"One of the keys to my success is my ability to identify key opportunities," said H.E. Al Shamsi. "I would like to extend this ability to Vivera in an advisory capacity to help them achieve their international business goals."

H.E. Al Shamsi holds a B.Sc. in Civil Engineering from the North Carolina State University, and an Executive Masters in Business Administration (EMBA). Among his distinguished accomplishments, he was chosen as a member of the International Who's Who of Professionals. Forbes has chosen him as one of the biggest business leaders in the Gulf Cooperation Counsel, while Arabian Business recognized him as one of the most influential leaders in regional business. H.E. Al Shamsi has also been a member of the American Business Council, the Canadian Business Council, and the National Society of Professional Engineers (NSPE)-USA, the Society of UAE Engineers and the Institute of Certified Management Accountants in the U.S.

Figure 1: His Excellency Salah Salem Bin Omair Al Shamsi

To view an enhanced version of this graphic, please visit:

About Vivera Pharmaceuticals, Inc.

Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELTâ„¢ sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELTâ„¢ drug delivery format with the goal of gaining FDA approval for its products.

The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.

For more information, visit .

Investor Relations Inquiries:
thinkHERO
Patrick Piette, CFA for Vivera Pharmaceuticals, Inc.
416-526-9911

Press Inquiries:
thinkHERO
Karin Elz, for Vivera Pharmaceuticals, Inc.
416-992-9848

48374_6c4c1211449d1915_logo.jpg

To view the source version of this press release, please visit

169

Click on, or paste the following link into your web browser,to view the associated documents /release/48374
News Source: Newsfile


01.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: Vivera Pharmaceuticals, Inc.
United States
EQS News ID: 883643

 
End of News DGAP News Service

883643  01.10.2019 

fncls.ssp?fn=show_t_gif&application_id=883643&application_name=news&site_id=research_pool
EN
01/10/2019

Underlying

300750Contemporary Amperex Technology (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Contemporary Amperex Technology (A)

 PRESS RELEASE

DGAP-News: ADL Bionatur Solutions Wins New Fermentation Client With Co...

DGAP-News: ADL Bionatur Solutions / Key word(s): Agreement ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million 02.12.2019 / 09:06 The issuer is solely responsible for the content of this announcement. ADL BIONATUR SOLUTIONS WINS NEW FERMENTATION CLIENT WITH CONTRACT REVENUES OF EUR 20 MILLION The agreement with a leading Swiss biotech company includes technology transfer, upscaling and industrial-scale production of high value-added innovative ingredients for the cosmetics and nutrition industry ADL to apply its expertise in a...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: Dozens Savings Plc 5.00% Secured Bonds due 2 December 2020 ISIN: GB00BL1GTZ11  Symbol: DS04 EMS: 1 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   W...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: SAPO PLC Ordinary Shares of GBP 0.01 ISIN: GB00B16GQJ90 Symbol: SAPO EMS: 5000 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   Website: ...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publishes open letter to Dr. Martin Haefner...

EQS Group-News: Dynamics Group AG / Key word(s): Statement/Corporate Action LIWET HOLDING AG publishes open letter to Dr. Martin Haefner in various Swiss Sunday newspapers 01.12.2019 / 05:59 Open letter to Dr. Martin Haefner Dear Mr Haefner We share your concern about the future of Schmolz+Bickenbach (S+B). The company urgently needs money, everyone - including Liwet - agrees. However, there is still time to find a constructive solution for S+B that is in the interest of all, not only one particular shareholder. Liwet is ready to rescue the company and the 10,000 jobs. Liw...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haef...

EQS Group-News: Dynamics Group AG / Schlagwort(e): Stellungnahme/Kapitalmaßnahme LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haefner in verschiedenen Schweizer Sonntagszeitungen 01.12.2019 / 05:59 Offener Brief an Dr. Martin Haefner Sehr geehrter Herr Haefner Wir teilen Ihre Sorge um die Zukunft von Schmolz+Bickenbach (S+B). Die Firma braucht dringend Geld; damit sind alle - auch Liwet - einverstanden. Noch bleibt Zeit, um eine konstruktive Lösung für S+B zu finden, die im Interesse aller Aktionäre ist, nicht nur eines einzigen. Liwet steht bereit, die Fir...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch